Document is current
Any future updates will be listed below
-
Authors
Litchfield, Kevin https://orcid.org/0000-0002-3725-0914
Reading, James L. https://orcid.org/0000-0001-5381-978X
Lim, Emilia L.
Xu, Hang
Liu, Po https://orcid.org/0000-0002-0183-2074
Al-Bakir, Maise
Wong, Yien Ning Sophia
Rowan, Andrew
Funt, Samuel A. https://orcid.org/0000-0002-7235-6319
Merghoub, Taha
Perkins, David
Lauss, Martin
Svane, Inge Marie
Jönsson, Göran
Herrero, Javier https://orcid.org/0000-0001-7313-717X
Larkin, James
Quezada, Sergio A. https://orcid.org/0000-0002-9763-1700
Hellmann, Matthew D. https://orcid.org/0000-0002-2670-9777
Turajlic, Samra https://orcid.org/0000-0001-8846-136X
Swanton, Charles https://orcid.org/0000-0002-4299-3018
-
Funding
Funding for this research was provided by:
Cancer Research UK (TRACERx)
RCUK | Medical Research Council (MR/P014712/1)
- License Information
-
More Information
Article History
Received: 30 July 2018
Accepted: 30 June 2020
First Online: 30 July 2020
Competing interests
: K.L., S.T., and C.S. have a patent on indel burden and checkpoint inhibitor response pending, and a patent on targeting of frameshift neoantigens for personalised immunotherapy pending. K.L. reports speaker fees from Roche Tissue Diagnostics. S.T. reports grants from Ventana, outside the submitted work. J.R. is a consultant for Achilles Therapeutics, and S.A.Q. is CSO and co-founder of Achilles Therapeutics. J.L. reports institutional research support from: BMS, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, Aveo, and consultancy support from: Achilles, AZ, Boston Biomedical, BMS, Eisai, EUSA Pharma, GSK, Ipsen, Imugene, Incyte, iOnctura, Kymab, Merck Serono, MSD, Nektar, Novartis, Pierre Fabre, Pfizer, Roche/Genentech, Secarna, Vitaccess. C.S. receives grant support from Pfizer, AstraZeneca, BMS, Roche-Ventana, Boehringer-Ingelheim, and Ono. C.S. acknowledges grant support from Pfizer, AstraZeneca, BMS, Roche-Ventana, Boehringer-Ingelheim, Ono Pharmaceutical and Archer Dx Inc. C.S. has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, and the Sarah Cannon Research Institute. C.S. has stock option in Apogen Biotechnologies, Epic Bioscience, GRAIL, and has stock options and is co-founder of Achilles Therapeutics. S.A.F. has received research support from AstraZeneca and Genentech/Roche, has served in a consulting or advisory role for Decibel, AstraZeneza, and Immunai, and has stock or other ownership interests in Urogen, Allogene Therapeutics, Neogene Therapeutics, Vaxigene, Kronos Bio, and Vida Ventures. M.D.H. receives research support from Bristol-Myers Squibb; has been a compensated consultant for Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Shattuck Labs, Immunai, Blueprint Medicines, Achilles, and Arcus; received travel support/honoraria from AstraZeneca, Eli Lilly, and Bristol-Myers Squibb; has options from Shattuck Labs, Immunai, and Arcus; has a patent filed by his institution related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. All other authors declare no competing interests.
